Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-875-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.74 million
Profitability
Miscellaneous
Employees104
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.04. The biopharmaceutical company earned $2.80 million during the quarter, compared to analysts' expectations of $1.09 million. Fate Therapeutics had a negative return on equity of 50.05% and a negative net margin of 934.70%. The company's quarterly revenue was up 180.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.37) EPS. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
16 Wall Street analysts have issued twelve-month target prices for Fate Therapeutics' stock. Their predictions range from $17.00 to $32.00. On average, they expect Fate Therapeutics' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 70.6% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.
What is the consensus analysts' recommendation for Fate Therapeutics?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.
Has Fate Therapeutics been receiving favorable news coverage?
News coverage about FATE stock has trended somewhat positive on Monday, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fate Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Fate Therapeutics.
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT) and Sangamo Therapeutics (SGMO).
What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- J. Scott Wolchko, President, Chief Executive Officer & Director
- Daniel D. Shoemaker, Chief Scientific Officer
- Yu Waye Chu, Vice President-Clinical Development
- Jim Beitel, Senior Vice President-Corporate Development
- Bahram Valamehr, Chief Development Officer
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $14.65.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $957.96 million and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.
What is Fate Therapeutics' official website?
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
